Von Willebrand Disease
38
2
3
25
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
10.5%
4 terminated out of 38 trials
86.2%
-0.3% vs benchmark
37%
14 trials in Phase 3/4
32%
8 of 25 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 25 completed trials
Clinical Trials (38)
Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease (VWD) Patients <6 Years of Age
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
Molecular and Clinical Profile of Von Willebrand Disease in Spain
Efficacy and Safety of Fanhdi®, a High-purity Von Willebrand Containing FVIII Concentrate, in Pediatric Patients With Von Willebrand Disease
Registry of Patients With Von WilLEbrand Disease Treated With Voncento®
Efficacy of Alphanate FVIII/VWF Concentrate in Type 3 Von Willebrand Patients
Performance Evaluation of Von Willebrand:Collagen-Binding Assays to Diagnose Von Willebrand Factor Deficiency in Patients With Increased Risk of Bleeding
rVWF IN PROPHYLAXIS
Recombinant Von Willebrand Factor in Subjects With Severe Von Willebrand Disease Undergoing Surgery
Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)
Pharmacokinetic, Safety and Tolerability Study of Recombinant Von Willebrand Factor / Recombinant Factor VIII Complex in Type 3 Von Willebrand Disease
Surveillance of Safety and Efficacy of Wilate in Patients With Von Willebrand Disease
Von Willebrand Disease in the Netherlands
Latin-American Von Willebrand Disease Registry
IL-11 in Adults With Von Willebrand Disease Undergoing Surgery
Willebrand International Non-interventional Global Surveillance
Study of Voncento® in Subjects With Von Willebrand Disease
A Study to Compare the Pharmacokinetics and Safety of Current Factor VIII Concentrate and Optivate® in Haemophilia A.
IL-11 in Women With Von Willebrand Disease and Refractory Menorrhagia
The Effect of the Nutraceutical "Hemofix" on the Coagulation System